Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274111 | 0.88 | PIM1 (0.36) | PIM1AKT2 | |
| SCHEMBL2022784 | 0.88 | PIM1 (0.39) | PIM1AKT2EGFRADORA2AADORA1 | |
| SCHEMBL15290720 | 0.85 | PIM1 (0.38) | PIM1AKT2PLK4 | |
| SCHEMBL13274115 | 0.82 | NPC1 (0.36) | PIM1AKT2ADORA2AADORA1 | |
| SCHEMBL2968986 | 0.81 | PIM1 (0.41) | PIM1AKT2EGFRADORA2AADORA1 | |
| SCHEMBL2961780 | 0.80 | PIM1 (0.39) | PIM1AKT2EGFRADORA2AADORA1 | |
| SCHEMBL13274112 | 0.79 | SREBF2 (0.44) | PIM1AKT2 | |
| SCHEMBL13274110 | 0.79 | PIM1 (0.34) | PIM1AKT2 | |
| SCHEMBL13274108 | 0.79 | MEN1 (0.35) | PIM1AKT2 | |
| SCHEMBL13330161 | 0.77 | PIM1 (0.49) | PIM1AKT2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249138-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140213595-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213595-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | PIM1 2836/4885AKT2 2913/4885EGFR 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.